[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.70

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.369

引用次数: 0

[Diagnostic utility of small-bowel capsule endoscopy in patients with gastrointestinal symptoms after allogeneic hematopoietic cell transplantation]. 【小肠胶囊内镜在异基因造血细胞移植后出现胃肠道症状患者中的诊断价值】。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.271

Satomi Shibata, Atsushi Jinguji, Masashi Shimabukuro, Takashi Toya, Kaoru Morita, Tomomi Toubai, Hiroaki Shimizu, Yuho Najima, Toshiro Iizuka, Noriko Doki

{"title":"[Diagnostic utility of small-bowel capsule endoscopy in patients with gastrointestinal symptoms after allogeneic hematopoietic cell transplantation].","authors":"Satomi Shibata, Atsushi Jinguji, Masashi Shimabukuro, Takashi Toya, Kaoru Morita, Tomomi Toubai, Hiroaki Shimizu, Yuho Najima, Toshiro Iizuka, Noriko Doki","doi":"10.11406/rinketsu.67.271","DOIUrl":"10.11406/rinketsu.67.271","url":null,"abstract":"We retrospectively evaluated the safety and diagnostic utility of small bowel capsule endoscopy (SBCE) in 45 patients (66 procedures) who developed gastrointestinal symptoms after allogeneic hematopoietic cell transplantation (allo-HCT). Despite a high proportion of patients with poor performance status (≥2: 43 procedures) and thrombocytopenia (platelet counts <20,000/µl in 10 procedures, <50,000/µl in 25 procedures), which are generally considered high-risk conditions for conventional esophagogastroduodenoscopy (EGD) and colonoscopy (CS), SBCE demonstrated a 0% adverse event rate and 89.2% complete small bowel observation rate, which are comparable to outcomes previously reported in non-transplant patients. Evaluation of all three gastrointestinal regions (stomach, small bowel, and colon), including exploratory observation, was feasible in 55 of 66 procedures, and small bowel lesions were identified in 28 procedures. In 6 of these (10.9%), lesions were confined exclusively to the small bowel, making them difficult to detect using conventional EGD and CS, and SBCE findings guided treatment decisions. In conclusion, SBCE can be safely performed in patients with gastrointestinal symptoms after allo-HCT and may provide unique diagnostic value, particularly in the evaluation of small bowel lesions.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 4","pages":"271-280"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Acquired pure red cell aplasia]. 获得性纯红细胞发育不全。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.566

Hideyuki Nakazawa

引用次数: 0

[Clonal hematopoiesis and myeloid neoplasms: from molecular basis to clinical implications]. 克隆造血与髓系肿瘤：从分子基础到临床意义。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.725

SungGi Chi

{"title":"[Clonal hematopoiesis and myeloid neoplasms: from molecular basis to clinical implications].","authors":"SungGi Chi","doi":"10.11406/rinketsu.67.725","DOIUrl":"https://doi.org/10.11406/rinketsu.67.725","url":null,"abstract":"Clonal hematopoiesis (CH) refers to the age-associated expansion of hematopoietic stem cell clones carrying somatic mutations that are commonly observed in myeloid malignancies. With the widespread use of next-generation sequencing, such mutations are now frequently detected even in individuals without overt hematologic abnormalities. CH in the absence of cytopenia or hematologic malignancy is defined as clonal hematopoiesis of indeterminate potential (CHIP), whereas CH accompanied by unexplained cytopenia is classified as clonal cytopenia of undetermined significance (CCUS), a recognized pre-malignant condition with a high risk of progression to myeloid neoplasms. The molecular landscape of CH is dominated by mutations in epigenetic regulators such as DNMT3A, TET2, and ASXL1, although spliceosome genes, signaling molecules, and DNA damage-response genes are also involved. Clonal expansion and malignant transformation are shaped by selective pressures including aging, chronic inflammation, and therapy-related DNA damage. Progression risk varies widely depending on mutation type, variant allele frequency, and clonal complexity, and several predictive models have been proposed. Beyond hematologic malignancies, CH has also been linked to cardiovascular and inflammatory diseases, highlighting its broader clinical relevance and the need for risk-adapted clinical strategies.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 7","pages":"725-731"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148665105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.703

Masanori Sakata, Masuho Saburi, Katsuya Kawano, Hiroyuki Takata, Yasuhiko Miyazaki, Eiichi Ohtsuka

引用次数: 0

[Gastric intramural hematoma during treatment with aspirin and anagrelide in a patient with essential thrombocythemia]. [原发性血小板增多症患者阿司匹林和阿纳格列特治疗期间胃壁内血肿]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.238

Atsuhiro Takagi, Satoru Mukai, Akihiro Umakoshi, Junpei Rikitake, Ritsuko Nakai, Masahisa Nakamura, Kazuo Hatanaka

{"title":"[Gastric intramural hematoma during treatment with aspirin and anagrelide in a patient with essential thrombocythemia].","authors":"Atsuhiro Takagi, Satoru Mukai, Akihiro Umakoshi, Junpei Rikitake, Ritsuko Nakai, Masahisa Nakamura, Kazuo Hatanaka","doi":"10.11406/rinketsu.67.238","DOIUrl":"10.11406/rinketsu.67.238","url":null,"abstract":"A 62-year-old man was diagnosed with JAK2 mutation positive essential thrombocythemia (ET) after developing cerebral infarction. He was treated with anagrelide and aspirin, with anagrelide increased to 5.5 mg/day, but platelet count remained around 700,000/µl. In July 2024, he presented to the emergency department with abdominal pain and vomiting. CT angiography showed a large gastric intramural hematoma as well as pseudoaneurysm from the right gastroepiploic artery. Following transcatheter arterial embolization, his symptoms improved, the hematoma decreased in size, and his condition stabilized. Gastric intramural hematoma is an extremely rare condition, often secondary to factors like anticoagulant therapy. Reports of cases diagnosed after resection of a suspected tumor highlight the importance of accurate diagnosis. Although thrombosis prevention is crucial in ET, anagrelide is associated with a higher risk of bleeding events than other therapies. To our knowledge, this is the first reported case of gastric intramural hematoma associated with ET and anagrelide.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 3","pages":"238-243"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera]. [真性红细胞增多症患者停用ropeg干扰素α -2b后持续血液学完全缓解]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.205

Masaki Maruta, Kento Mori, Koji Oka, Yuya Masuda, Junichi Kato, Tatsuya Konishi, Shogo Nabe, Yukihiro Miyazaki, Toshiki Ochi, Jun Yamanouchi, Katsuto Takenaka

{"title":"[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].","authors":"Masaki Maruta, Kento Mori, Koji Oka, Yuya Masuda, Junichi Kato, Tatsuya Konishi, Shogo Nabe, Yukihiro Miyazaki, Toshiki Ochi, Jun Yamanouchi, Katsuto Takenaka","doi":"10.11406/rinketsu.67.205","DOIUrl":"10.11406/rinketsu.67.205","url":null,"abstract":"We report two cases of polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg-IFN) in which hematologic control was maintained without therapy after treatment discontinuation. The patients achieved complete response (CR) at 14 and 22 weeks after treatment initiation, respectively. After discontinuation of ropeg-IFN, Patient 1 has maintained hematocrit (Ht) <45% for 3 years and 3 months, while patient 2 has maintained CR for 1 year and 5 months. Clinical trials have demonstrated that ropeg-IFN reduces the JAK2 V617F allele burden, which is recognized as an independent risk factor for disease progression and thrombosis, apart from traditional factors such as age and prior cardiovascular events. To improve the prognosis of PV, it is essential to accumulate clinical evidence on trends in JAK2 V617F allele burden and the conditions required to maintain hematologic control after discontinuation of ropeg-IFN therapy in real-world settings.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 3","pages":"205-208"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects]. [成熟NK/ t细胞淋巴瘤的治疗前景：日本的治疗结果和未来展望]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.998

Ayumi Fujimoto

{"title":"[Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects].","authors":"Ayumi Fujimoto","doi":"10.11406/rinketsu.67.998","DOIUrl":"10.11406/rinketsu.67.998","url":null,"abstract":"Mature NK/T-cell lymphomas are a rare group of lymphoma subtypes, represented by extranodal NK/T-cell lymphoma (ENKL) and aggressive NK-cell leukemia (ANKL). Both subtypes are strongly associated with Epstein-Barr virus and show a high prevalence, particularly in East Asia and Central and South America. In Japan, ENKL currently accounts for approximately 1% of all malignant lymphomas, whereas ANKL is even rarer, accounting for approximately 0.1%. ENKL and ANKL share many clinical and pathological features. However, as evidence regarding differences in molecular biological characteristics, including genetic and chromosomal abnormalities, has gradually accumulated, they have been recognized as distinct disease entities since the 2001 WHO classification (3rd edition). Since the 2000s, the treatment of ENKL has markedly advanced with the development of non-anthracycline-based regimens. In Japan, RT-2/3DeVIC for localized-stage ENKL and SMILE for stage IV and relapsed/refractory ENKL were developed and remain the current standard of care. In contrast, because ANKL is a rare disease and reports on its treatment are limited, it is usually treated using strategies for advanced-stage ENKL. This review focuses on ENKL and ANKL, providing an overview of their disease characteristics, evolving treatment and prognosis, and future challenges and perspectives.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 8","pages":"998-1008"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Hematological diseases caused by excessive complement activation]. 【补体活化过度引起的血液病】。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2026-01-01 DOI: 10.11406/rinketsu.67.950

Norimitsu Inoue

{"title":"[Hematological diseases caused by excessive complement activation].","authors":"Norimitsu Inoue","doi":"10.11406/rinketsu.67.950","DOIUrl":"10.11406/rinketsu.67.950","url":null,"abstract":"The complement system, which plays a key role in innate immunity, facilitates the elimination of foreign and endogenous substances in the body. Consequently, while a balance between complement activation and regulation is typically maintained, a disruption of this balance can lead to various diseases. Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS) are diseases in which abnormal complement regulatory factors cause excessive complement activation. To accurately diagnose diseases such as aHUS, international standard complement tests including activation markers such as Ba and sC5b-9 are used. The Japanese Society for Complement Research has contributed to the standardization of the International Complement Society and has established this testing system in Japan. In the present study, we revealed that the Ba level serves as a good predictive marker for the onset of thrombotic microangiopathy, a complication that typically occurs following hematopoietic stem cell transplantation. We also showed that complement activation levels rise more frequently postpartum than during pregnancy. Considering the growing number of drugs targeting the complement pathway, it is speculated that these complement markers will become available for testing in clinical settings in Japan.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"67 8","pages":"950-956"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0